

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT06979453

Status	RECRUITING
Phase	Phase 3
Sponsor	Bristol-Myers Squibb
Enrollment	366 participants

Key Eligibility Criteria

Inclusion (8)

- Participants must have stable plaque psoriasis for 6 months or more prior to Screening.
 - Participants must have moderate to severe psoriasis defined by:
 - i) Psoriasis Area and Severity Index (PASI) \geq 12, at screening visit and Day 1.
 - ii) Static Physician's Global Assessment (sPGA) \geq 3, at screening visit and Day 1.
 - iii) Body Surface Area (BSA) \geq 10% involvement, at screening visit and Day 1.
- ... and 3 more (see full listing online)

Exclusion (12)

- Participants must not weigh $<$ 30.0 kg at Screening and Day 1.
 - Participants must not have non-plaque psoriasis (ie, guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis) or any skin condition other than plaque psoriasis that could interfere with assessments of treatment effect at Screening or Day 1.
 - Participants must not have a history of serious bacterial, fungal, or viral infection requiring hospitalization and intravenous (IV) antimicrobial treatment within 60 days prior to Day 1.
 - Participants must not have any untreated bacterial infection within 60 days prior to Day 1.
 - Participants must not have any ongoing evidence of chronic bacterial infection (eg, chronic pyelonephritis, chronic osteomyelitis, chronic bronchiectasis).
- ... and 7 more (see full listing online)

Locations (116 total)

Local Institution - 0261, Birmingham, Alabama, United States
Local Institution - 0041, Birmingham, Alabama, United States
Local Institution - 0053, Phoenix, Arizona, United States
... and 113 more locations